- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07508787
Uno studio che confronta Siplizumab con Globulina Anti-Timociti di Coniglio per aiutare l'organismo ad accettare un trapianto di rene (MODERNIZE1)
Studio di fase 2b, randomizzato, multicentrico, in doppio cieco, per la determinazione del dosaggio, controllato con attivo, di Siplizumab (TCD601) rispetto alla Globulina Anti-Timocita di Coniglio in riceventi di trapianto renale che richiedono terapia di induzione e ricevono la terapia immunosoppressiva standard con Tacrolimus, Acido Micofenolico e Corticosteroidi
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are:
How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)?
How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up.
How does the body respond to siplizumab after dosing at each of the 2 dose levels?
How does siplizumab work in the body compared to rATG?
Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant.
Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws.
Participants will be monitored for 12 months after transplant surgery.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Approximately 120 renal transplant candidates requiring induction therapy will be enrolled 1:1:1 to receive 1 of 2 dose levels of siplizumab or to the comparator rATG.
Randomization will be stratified by donor status (living vs donation after brain death vs donation after cardiac death) to ensure similar proportions of donor types in each study arm. All participants will also receive:
- A triple regimen (TAC, MPA, and CS) of background immunosuppressive therapy for the duration of the study.
- Premedication prior to study treatment infusions.
- Infection prophylaxis
This clinical trial will evaluate the safety of an anti-cluster of differentiation 2 (CD2) monoclonal antibody, siplizumab, compared to rATG as induction therapy in renal transplant recipients.
Following hospital discharge, participants will undergo assessments and procedures as indicated in the protocol through Month 12 or EOS, unless more frequent visits are required per local SoC or for laboratory specimen collection.
Safety assessments will include physical examinations, ECGs, vital signs, viral surveillance and monitoring, standard clinical laboratory evaluations completed centrally (hematology, clinical chemistry, urinalysis), and AE/SAE monitoring.
Final analysis will be performed when all participants have completed 12-month follow-up visits post-transplant or have otherwise ended the trial. This analysis will be performed to evaluate the safety of siplizumab at 2 dose levels compared to rATG.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasile, 30150-320
- Reclutamento
- Santa Casa Demisericordia de Belo Horizonte
-
Contatto:
- Pedro Macedo de Souza
- Numero di telefono: +55 (31) 3238-8975
- Email: pmacedosouza@gmail.com
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasile, 90035-903
- Reclutamento
- Hospital de Clinicas de Porto Alegre
-
Contatto:
- Research Coordinator
- Numero di telefono: +55 51 3359-6253
- Email: l-genetica@hcpa.edu.br
-
Porto Alegre, Rio Grande do Sul, Brasile, 90020-090
- Reclutamento
- Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer
-
Contatto:
- Research Coordinator
- Numero di telefono: +55 51 3214-8640
- Email: pesquisa@santacasa.org.br
-
-
São Paulo
-
São José do Rio Preto, São Paulo, Brasile, 15090-000
- Reclutamento
- Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa
-
Contatto:
- Research Coordinator
- Numero di telefono: +55 (17) 3201-5054
- Email: osvaldo.junior@centrodepesquisacip.com.br
-
São Paulo, São Paulo, Brasile, 04038-002
- Reclutamento
- Fundação Oswaldo Ramos - Hospital do Rim (HRIM)
-
Contatto:
- Research Coordinator
- Numero di telefono: +55 (11) 5087-8110
- Email: hospital@hrim.com.br
-
-
-
-
-
Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitari Vall D'Hebron
-
Contatto:
- Study Coordinator
- Numero di telefono: +34 932746000
- Email: assajos.nefrologia@vhir.org
-
Córdoba, Spagna, 14004
- Reclutamento
- Hospital Universitario Reina Sofía
-
Contatto:
- Álvaro Torres, MD
- Numero di telefono: +34 957010440
- Email: nefro.hrs.sspa@juntadeandalucia.es
-
Málaga, Spagna, 29010
- Reclutamento
- Hospital Universitario Regional de Malaga
-
Contatto:
- Study Coordinator
- Numero di telefono: +34 951291174
- Email: estudios.clinicos@ibima.eu
-
-
-
-
California
-
Los Angeles, California, Stati Uniti, 90033
- Reclutamento
- Keck Hospital of the University of Southern California
-
Contatto:
- Melissa Ramos
- Numero di telefono: 323-442-7983
- Email: Melissa.Ramos@med.usc.edu
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- University of California - Los Angeles, Connie Frank Kidney Transplant Center
-
Contatto:
- Suphamai Bunnapradist, MD
- Numero di telefono: 310-794-8516
- Email: bunnapradist@mednet.ucla.edu
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- UC Davis Medical Center
-
Contatto:
- Timothy Huynh, Clinical Research Coordinator
- Numero di telefono: 916-703-4471
- Email: ttihuynh@health.ucdavis.edu
-
-
Florida
-
Tampa, Florida, Stati Uniti, 33606
- Reclutamento
- Tampa General Hospital
-
Contatto:
- Jennifer Schmidt, BSN, RN
- Numero di telefono: 813-844-7041
- Email: jenniferanilsen@tgh.org
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University Hospital
-
Contatto:
- Emily Temponi, Study Coordinator
- Numero di telefono: 404-712-1114
- Email: emily.k.temponi@emory.edu
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Reclutamento
- University of Kansas Hospital
-
Contatto:
- Adam Schooley, MA, CCRP
- Numero di telefono: 913-588-1699
- Email: aschooley@kumc.edu
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Reclutamento
- University of Kentucky Healthcare
-
Contatto:
- Malay Shah, MD
- Numero di telefono: 859-338-1615
- Email: malay.shah@uky.edu
-
-
Louisiana
-
Metairie, Louisiana, Stati Uniti, 70006
- Reclutamento
- Tulane Medical Center
-
Contatto:
- Nicole Jackson
- Numero di telefono: 504-988-5344
- Email: njackson3@tulane.edu
-
-
Massachusetts
-
Worcester, Massachusetts, Stati Uniti, 01655
- Reclutamento
- UMass Chan Medical Center
-
Contatto:
- Anil Chandraker, MD
- Numero di telefono: 508-334-7087
- Email: anil.chandraker4@umassmed.edu
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan - Michigan Medicine
-
Contatto:
- Nerissa Reister, Clinical Research Coordinator
- Numero di telefono: 734-763-5718
- Email: naflow@med.umich.edu
-
Detroit, Michigan, Stati Uniti, 48202
- Reclutamento
- Henry Ford Health
-
Contatto:
- Matthew Callaghan
- Numero di telefono: 313-916-4596
- Email: mcallag2@hfhs.org
-
-
New Jersey
-
Livingston, New Jersey, Stati Uniti, 07039
- Reclutamento
- Cooperman Barnabus Medical Center
-
Contatto:
- Jayrol Mock, APN
- Numero di telefono: 973-322-2339
- Email: Jayrol.Mock2@rwjbh.org
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- New York Presbyterian - Columbia University Irving Medical School
-
Investigatore principale:
- Lloyd Ratner, MD
-
Contatto:
- Angela Sanchez, CRC
- Numero di telefono: 212-305-3839
- Email: as5546@cumc.columbia.edu
-
Contatto:
- Theresa Lukose, Research Director
- Numero di telefono: 212-305-3839
- Email: tt2103@cumc.columbia.edu
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- New York Presbyterian - Weill Cornell Medical Center
-
Contatto:
- Jennifer Lee
- Numero di telefono: 212-746-0192
- Email: jel9109@nyp.org
-
Contatto:
- Meredith Aull
- Numero di telefono: 212-746-5330
- Email: mea9008@med.cornell.edu
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Reclutamento
- Duke University Medical Center
-
Contatto:
- Lynnette Moats
- Numero di telefono: 919-949-6574
- Email: lynnette.moats@duke.edu
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- University of Texas Southwestern Medical Center
-
Contatto:
- David Wojciechowski, DO
- Numero di telefono: 214-645-7846
- Email: David.Wojciechowski@UTSouthwestern.edu
-
-
Virginia
-
Falls Church, Virginia, Stati Uniti, 22042
- Reclutamento
- Inova Fairfax Hospital
-
Contatto:
- Alma Khan, MSN, CCRC
- Numero di telefono: 703-776-5912
- Email: Alma.Khan2@inova.org
-
Richmond, Virginia, Stati Uniti, 23298
- Reclutamento
- Virginia Commonwealth University Health
-
Contatto:
- Meron Zeleke
- Numero di telefono: 804-628-4969
- Email: Meron.Zeleke@vcuhealth.org
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195
- Reclutamento
- University of Washington Medical Center
-
Contatto:
- Belinda Pan, Research Coordinator
- Numero di telefono: 206-598-1562
- Email: bcpan@uw.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Recipients of a renal allograft from a non-HLA identical living or deceased donor.
- Recipients of a kidney with a cold ischemia time < 30 hours; hypothermic machine perfusion within the same timeframe is acceptable.
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, must agree to use highly effective methods of contraception.
Exclusion Criteria:
- Transplant recipients seronegative for EBV.
- Transplant recipients receiving a kidney from a non-heart beating donor (ie, DCD) whose organ is retrieved from an uncontrolled DCD or whose donor age > 55 years of age.
- Multi-organ transplant recipients (eg, kidney-pancreas, organ other than kidney), dual-kidney transplant recipients, recipients with more than one prior kidney transplant, or hematopoietic stem cell transplantation recipients.
- Presence of current or historical DSA via single-antigen bead assay or local SoC. The MFI cut-off value used to determine the presence of DSA will be defined as per the institutional SoC. Results within 3 months prior to transplant are acceptable.
- Crossmatch positive (isolated positive B cell crossmatches are not an exclusion criterion).
- ABO-incompatible recipient.
- Administration of complement inhibitor therapy within 6 months prior to the transplant, or likely to require treatment with complement inhibitor therapy during the study.
- Participants receiving immunosuppressive therapies prior to transplant for pre-existing conditions must be candidates for the protocol-defined regimen.
- History of malignancy of any organ system, except for localized excised non-melanomatous skin lesions or carcinoma in situ of the cervix.
- Seropositive for human immunodeficiency virus or hepatitis B surface antigen. Participants who are seropositive for hepatitis C virus (HCV) are excluded without proof of sustained viral response after anti-HCV treatment.
- Recipient of a kidney from a donor who tests positive for human immunodeficiency virus or hepatitis B surface antigen/hepatitis B core protein.
- History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (eg, siplizumab, rATG, TAC, MPA derivatives, CS).
- Evidence of active tuberculosis (TB) infection (participants with a history of latent TB may become eligible after treatment with anti-TB therapy according to national guidelines).
- Participants with severe systemic infection(s), at the time of screening or within 2 weeks prior to randomization
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Bassa dose di siplizumab
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Altri nomi:
|
|
Sperimentale: Alta dose di siplizumab
|
A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class
Altri nomi:
|
|
Comparatore attivo: Globulina anti-timociti di coniglio
|
An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Assessment of the safety of 2 dose levels of siplizumab versus rATG.
Lasso di tempo: 12 months
|
Number and percentage of participants at 12 months post-transplant experiencing adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). |
12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
|
• Grade of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
|
• Severity of BPAR. |
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
|
|
12 months
|
|
Assessment of the incidence of composite efficacy failure (defined as death, graft loss, biopsy-proven acute rejection [BPAR], or loss-to-follow-up) and their individual components.
Lasso di tempo: 12 months
|
• Number of participants requiring for-cause renal allograft biopsy assessments over 12 months post-transplant. |
12 months
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Lasso di tempo: 12 weeks
|
Siplizumab Cmax (maximum blood concentration) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacokinetics (PK) of 2 dose levels of siplizumab.
Lasso di tempo: 12 weeks
|
Siplizumab AUC (area under the concentration-time curve) over 12 weeks post-transplant. |
12 weeks
|
|
Assessment of the pharmacodynamics (PD) of 2 dose levels of siplizumab versus rATG.
Lasso di tempo: 12 months
|
Depletion and recovery of lymphocyte count by subset (total lymphocytes; CD3+, CD4+, and CD8+ T cells; CD19+ B cells; CD56+ NK cells) over 12 months post-transplant. |
12 months
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- TCD601B205
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .